UTSW HP [13-C] Pyruvate Injection in HCM (NCT03057002) | Clinical Trial Compass
CompletedNot Applicable
UTSW HP [13-C] Pyruvate Injection in HCM
United States7 participantsStarted 2018-05-01
Plain-language summary
The study objective is to identify the earliest changes in energy substrate metabolism in patients with cardiomyopathies (CMP). To achieve this objective, we plan first to test the hypothesis that patients with CMP present focal alterations in myocardial hyperpolarized \[1-13C\]pyruvate flux.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria for Control Subjects:
* Subjects who are 18.
* Subjects who have the ability to understand and the willingness to sign a written informed consent.
* While all races and ethnicities will be included, subjects must be able to read and speak the English language. Once the protocol is established, Spanish-speaking participants will be included.
* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Inclusion Criteria for participants with Cardiomyopathy:
* Subjects who are 18.
* Subjects who have the ability to understand and the willingness to sign a written informed consent.
* While all races and ethnicities will be included, subjects must be able to read and speak the English language. Once the protocol is established, Spanish-speaking participants will be included.
* Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Exclusion criteria:
* Subjects who are receiving any other inves…
What they're measuring
1
Hyperpolarized [1-13C]pyruvate flux
Timeframe: Screening (Baseline) and 1 day of Study Visit
Trial details
NCT IDNCT03057002
SponsorUniversity of Texas Southwestern Medical Center